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ABSTRACT 
The present investigation was aimed to compare various phospholipids and different methods that would be appropriate to produce 
liposomes having vesicle size in the range of 200-300 nm, PDI less than 0.500, maximum entrapment and delayed release of 
lamivudine. The phospholipids employed were Phospholipon® 90G, Phospholipon® 90H, 1,2-Dimyristoyl-sn-glysero-3-
phosphocholine (DMPC) and 1,2-Dipalmitoyl-sn-glysero-3-phosphocholine (DPPC). They were used in various molar ratio with 
cholesterol and blank liposomes were prepared initially by thin film hydration and ether injection method. The thin film hydration 
method was only found to be appropriate to produce liposome of desired size and PDI. Hence, the molar ratios of employed 
phospholipids:cholesterol that produced liposomes as per the expected parameters was then used to load lamivudine. The method of 
preparation, phospholipid: cholesterol molar ratio, hydrations above transition temperature and hydration time were showed direct 
influence on vesicle size, PDI, percentage encapsulation and in-vitro release. Phospholipon® 90H: cholesterol: lamivudine in the 
molar ratio 1:2:1 produced liposomes having desired vesicle size and PDI with maximum drug entrapment and sustained release. 
The encapsulation efficiency of drug in liposomes was in the order of Phospholipon® 90H> Phospholipon® 90G > DPPC > DMPC. 
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INTRODUCTION 
Lamivudine (3TC) is an antiretroviral agent, used either 
alone or in combination for a prolonged period in the 
treatment of AIDS (Acquired immunodeficiency 
syndrome). HIV mainly found in CNS, lymphatic 
system, liver, lungs, T-lymphocytes and macrophages 
etc
1
. It is difficult for majority of drug to reach and 
maintain its therapeutic concentration at the HIV 
localized site by conventional therapy and short half 
life
2
, which lead to non compliance to the therapy, and 
increase in viral load. AIDS requires lifetime treatment 
and development of resistance demands further rise in 
the dose
3
. High dose of 3TC is required to maintain 
minimum effective concentration at the HIV reservoir to 
control the viral load. Frequent administration results in 
to higher interaction even with uninfected tissues, 
leading to untoward side effects.  
Therefore, to restrict its stay in free form, earlier workers 
have attempted to incorporate it in special formulations 
such as nanoparticles
4-7
, ethosomes
8
, liposomes
9
, 
dendrimers
10
, neosomes
11 
etc, so that control and 
targeted delivery can be achieved. Among these, 
nanoparticles tend to aggregate due to small size, and 
that limits the release of entrapped drug or some time 
leads to burst release. Multiple molecules attach to 
dendrimers leading to inconsistent batches during large 
scale production. Other issues related to dendrimers are 
deterioration of material homogeneity
12
, 
biocompatibility and cytotoxicity
13,14
. Neosomes suffers 
stability problems
15-16
.  
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Liposomes are the concentric vesicles in which an 
aqueous phase is entirely entrapped by a lipid layer
17
. 
The outer lipid layer is usually made of phospholipids 
having a hydrophilic head and hydrophobic tail
18
. 
Liposomes are able to encapsulate hydrophilic drug in 
their interior aqueous compartment and lipophillic drug 
with in lipid bilayer
19,20
. Liposome encapsulates the drug 
and thereby reduces its toxicity, and protects it against 
rapid degradation in the blood circulation
21
. Liposome 
helps to increase therapeutic index of antiviral agent
22-25
. 
Also help to reduce the dose and consequent side 
effects
26
. On interaction with the cell membrane, the 
liposomes enter the cell by diffusion process and release 
the drug to the cell. Moreover, liposomes are taken up 
by RES system which leads to rapid uptake of 
liposomes
27
, where HIV normally harbors
1,28
. Therefore, 
liposomal formulation is preferred for the reason that 
water soluble 3TC is entrapped in the centre, and it is 
surrounded by concentric phospholipid layer/s. 
Engulfment of such liposomes by microphages will 
ensure targeted delivery of 3TC to the cells with high 
viral load. Moreover, liposomes being made up of 
phospholipids are well accepted by the body and have no 
clinical reports of allergic reactions when administered 
by parenteral route. Therefore it was thought worthwhile 
to prepare 3TC loaded liposome for targeting the 
macrophages by parenteral route. 
The literature documents a long list of phospholipids. 
Interestingly, except the common chain structure, there 
exist diversity in their single unit forming the chain and 
hence their ability to accommodate lipophilic or 
hydrophilic agents differs extensively. In the preparation 
of liposome the earlier workers used wide range of 
phospholipids such as Phospholipon
®
 90G, 
Phospholipon
®
 90H, 1,2-Dimyristoyl-sn-glysero-3-
phosphocholine (DMPC) and 1,2-Dipalmitoyl-sn-
glysero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-
glycero-3-phosphocholine (DSPC)  etc. However, due to 
isolated studies it is difficult to compare which 
phospholipid can produce 3TC loaded liposomes with 
the desired characteristics. Thin film hydration and ether 
injection method are the most employed methods in the 
preparation of liposomes. Therefore, we initially 
compared these methods by using various concentrations 
of phospholipids and cholesterol. The batches of 
liposomes produced by each method were later 
compared for vesicle size and PDI. Many literatures 
documented that uptake of liposomes by MPS cells was 
improved with increased size
29-30
. Therefore, the method 
and phospholipid that produced vesicles of size in the 
range of 200-300 nm with PDI below 0.500 was then 
employed to prepare 3TC loaded liposomes. These 3TC 
loaded liposomes were further evaluated for drug 
entrapment and in-vitro release.  
MATERIALS AND METHODS 
Materials                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
Phospholipon
®
 90G, Phospholipon
®
 90H, DMPC and 
DPPC were the gift samples from Lipoid GmbH 
Germany, and 3TC was the gift sample from Cipla 
Limited, Kurkumbh India. All other used chemicals 
were of HPLC grade. Fresh double distilled water was 
used throughout the experiment. 
Preparation of empty liposomes 
1. Thin film hydration method  
 Phospholipid and cholesterol in various molar ratios 
were dissolved in chloroform in pear shape flask with 
gentle shaking. Chloroform was evaporated in a rotary 
flask evaporator (Buchi type) above the transition 
temperature of lipids at 120 rpm to get a thin film in the 
flask. This film was kept overnight under vacuum to 
remove traces of solvents if any. The casted film was 
then hydrated by adding 10 ml of phosphate buffer 
saline (pH7.4). To disperse the film in the solution, the 
flask was again rotated on the rotary flask evaporator 
without vacuum above the transition temperature of 
phospholipid until a white milky suspension was 
obtained
31
. To further reduce the size of liposomes, the 
dispersion was sonicated for 1 min, by using bath 
sonicator (Imeco Ultrasonics). After sonication, the 
suspension was subjected to the evaluation of vesicle 
size and PDI. 
The rotational speed, time period for hydration and 
period of sonication employed in this method is based on 
the results of preliminary studies. The influence of the 
molar ratio of Phospholipid: cholesterol on vesicles size 
and PDI is as shown in Table 1.  
2. Ether injection method  
Phospholipid and cholesterol in various molar ratios 
were dissolved in diethyl ether. In a beaker phosphate 
buffer saline (10 ml, pH7.4) was continuously stirred 
with a magnetic stirrer and its temperature was 
maintained between 55-60
o
C. With the help of syringe 
the solution of phospholipid and cholesterol was then 
slowly injected to disperse the solution in phosphate 
buffer saline (pH7.4). Beaker was continuously stirred 
on magnetic stirrer at 55-60
o
C until the ether got 
completely evaporated and a milky dispersion was 
obtained
32,33
. The dispersion was subjected to sonication 
for 1 min. The vesicle size and PDI of the liposomes was 
then evaluated. The influence of the molar ratio of 
Phospholipid: cholesterol on vesicles size and PDI is as 
shown in Table 2.  
Evaluation of empty liposomes 
Appearance 
The appearance of the liposomal suspension was 
assessed by naked eyes. 
Vesicle size and PDI 
Aliquots (1ml) of the samples were serially diluted with 
phosphate buffer saline (pH7.4) to obtain 1000-fold 
dilution, and the globule size and size distribution was 
accessed by using Malvern particle size analyzer 
(Malvern Nano ZS90, Malvern, UK). Each study was 
carried out in triplicate (Mean±SD, n=3). 
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Table 1: Liposome formulations prepared by thin film hydration method 
Sr. 
No. 
Batch 
code 
Phospholipid 
 
Molar Ratio of 
phospholipid: 
cholesterol 
Appearance 
Vesicle size 
(nm) 
PDI 
1.  LH1 Phospholipon
®
90H 0.5: 1.5 
Milky white 
dispersion 
276.0±21.6 0.492±0.043 
2.  LH2 Phospholipon
®
90H 1.0: 1.0 
Milky white 
dispersion 
259.0±10.3 0.362±0.042 
3.  LH3 Phospholipon
®
90H 1.0: 2.0 
Milky white 
dispersion 
268.0±13.5 0.267±0.028 
4.  LH4 Phospholipon
®
90H 1.5: 0.5 
Milky white 
dispersion 
289.1±15.6 0.620±0.022 
5.  LH5 Phospholipon
®
90H 2.0: 1.0 
Milky white 
dispersion 
374.1±14.5 1.000±0.045 
6.  LG1 Phospholipon
®
90G 0.5: 1.5 
Milky white 
dispersion 
302.1±09.6 0.500±0.021 
7.  LG2 Phospholipon
®
90G 1.0: 1.0 
Milky white 
dispersion 
264.0±25.2 0.450±0.037 
8.  LG3 Phospholipon
®
90G 1.0: 2.0 
Milky white 
dispersion 
231.5±22.8 0.308±0.051 
9.  LG4 Phospholipon
®
90G 1.5: 0.5 
Milky white 
dispersion 
299.6±19.7 0.590±0.032 
10.  LG5 Phospholipon
®
90G 2.0: 1.0 
Milky white 
dispersion 
392.0±25.6 0.281±0.061 
11.  LP1 DPPC 0.5: 1.5 
Milky white 
dispersion 
278.2±26.1 0.220±0.045 
12.  LP2 DPPC 1.0: 1.0 
Milky white 
dispersion 
327.0±24.8 0.263±0.081 
13.  LP3 DPPC 1.0: 2.0 
Milky white 
dispersion 
368.2±31.2 0.436±0.073 
14.  LP4 DPPC 1.5: 0.5 
Milky white 
dispersion 
317.1±29.3 0.890±0.048 
15.  LP5 DPPC 2.0: 1.0 
Milky white 
dispersion 
431.0±31.7 0.420±0.081 
16.  LM1 DMPC 0.5: 1.5 
Milky white 
dispersion 
321.0±37.9 0.800±0.039 
17.  LM2 DMPC 1.0: 1.0 
Milky white 
dispersion 
352.0±20.9 0.434±0.091 
18.  LM3 DMPC 1.0: 2.0 
Milky white 
dispersion 
280.1±21.2 0.590±0.034 
19.  LM4 DMPC 1.5: 0.5 
Milky white 
dispersion 
321.2±26.8 0.212±0.082 
20.  LM5 DMPC 2.0: 1.0 
Milky white 
dispersion 
301.1±41.8 0.362±0.029 
(Mean ±SD, n=3) 
 
Preparation of 3TC loaded liposomes 
The preliminary studies revealed that thin film hydration 
method produced the vesicle of 200-300 nm size with 
the PDI below 0.500. The molar ratio of phospholipid: 
cholesterol which produced liposomes of such size and 
PDI is as shown in Table 3. In ether injection method, 
none of the molar ratio of phospholipid: cholesterol 
could produce vesicles in the desired range, and the PDI 
was above 0.500. Therefore, thin film hydration method 
was selected as the carrier to load 3TC. The molar ratio 
of phospholipid to cholesterol as shown in Table 3 was 
used for this purpose. 3TC was incorporated in the 
liposomes by the following procedure.      
The test drug was dissolved in phosphate buffer saline 
(10ml, pH7.4), and was then added to a pear shape flask, 
the wall of which had a deposit of a film left over after 
the total evaporation of the solvent. The flask containing 
drug solution in phosphate buffer saline (pH7.4) and the 
film on the wall was then slowly rotated on the rotary 
flask evaporator without vacuum above the transition 
temperature of phospholipid so that the film gets 
converted in to the liposomal vesicles entrapping the 
drug containing solution. To further reduce the size of 
liposomes, the dispersion was sonicated for 1 min, by 
using bath sonicator (Imeco Ultrasonics). The 3TC 
loaded liposomes were then subjected to the evaluation 
of vesicle size, PDI, % encapsulation efficiency, TEM 
study, zeta potential, entrapment efficiency and in-vitro 
release. The formulation details of various batches of 
3TC loaded liposomes are as shown in Table 3. 
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Table 2: Liposomal formulations prepared by ether injection method 
Sr. 
No. 
Batch 
code 
Phospholipid 
 
Molar Ratio of 
phospholipid: 
cholesterol 
Appearance 
Vesicle size 
(nm) 
PDI 
1.  EH1 Phospholipon
®
90H 0.5: 1.5 
Milky white 
dispersion 
342.7±072.5 0.394±0.035 
2.  EH2 Phospholipon
®
90H 1.0: 1.0 
Milky white 
dispersion 
313.3±053.8 0.281±0.048 
3.  EH3* Phospholipon
®
90H 1.0: 2.0 ---- ---- ---- 
4.  EH4* Phospholipon
®
90H 1.5: 0.5 ---- ---- ---- 
5.  EH5* Phospholipon
®
90H 2.0: 1.0 ---- ---- ---- 
6.  EG1 Phospholipon
®
90G 0.5: 1.5 
Milky white 
dispersion 
476.6±039.2 1.000±0.039 
7.  EG2 Phospholipon
®
90G 1.0: 1.0 
Milky white 
dispersion 
401.0±041.5 0.392±0.057 
8.  EG3* Phospholipon
®
90G 1.0: 2.0 ---- ---- ---- 
9.  EG4* Phospholipon
®
90G 1.5: 0.5 ---- ---- ---- 
10.  EG5* Phospholipon
®
90G 2.0: 1.0 ---- ---- ---- 
11.  EP1 DPPC 0.5: 1.5 
Milky white 
dispersion 
347.9±051.4 0.445±0.038 
12.  EP2* DPPC 1.0: 1.0 ---- ---- ---- 
13.  EP3* DPPC 1.0: 2.0 ---- ---- ---- 
14.  EP4* DPPC 1.5: 0.5 ---- ---- ---- 
15.  EP5* DPPC 2.0: 1.0 ---- ---- ---- 
16.  EM1* DMPC 0.5: 1.5 ---- ---- ---- 
17.  EM2 DMPC 1.0: 1.0 
Milky white 
dispersion 
456.8±029.7 0.854±0.074 
18.  EM3 DMPC 1.0: 2.0 
Milky white 
dispersion 
473.0±024.7 0.643±0.091 
19.  EM4* DMPC 1.5: 0.5 ---- ---- ---- 
20.  EM5* DMPC 2.0: 1.0 ---- ---- ---- 
*Phase separation occurred in these batches hence further evaluation was not possible.  (Mean ±SD, n=3) 
Table 3: Formulation and evaluation of 3TC loaded liposomes 
Formulation 
code 
Phospholipid 
Molar Ratio of 
phospholipid: 
cholesterol: 
drug 
Appearance 
Vesicle 
size 
PDI 
Zeta 
potential 
% 
entrapment 
TCLH3 Phospholipon®90H 1.0:2.0:01 
Milky white 
dispersion 273.0±2.04 0.267±0.019 -13.7±0.3 63.64±03.29 
TCLG3 Phospholipon®90G 1.0:2.0:01 
Milky white 
dispersion 241.5±2.12 0.208±0.024 -11.3±0.2 57.07±01.54 
TCLP1 DPPC 0.5:1.5:01 
Milky white 
dispersion 286.2±3.28 0.220±0.036 -11.6±0.4 49.13±02.90 
TCLM3 DMPC 1.0:2.0:01 
Milky white 
dispersion 
261.2±2.82 0.212±0.068 -10.5±0.2 37.35±02.56 
(Mean ±SD, n=3) 
 
Evaluation of 3TC loaded liposomes 
1. Percent encapsulation efficiency  
The liposomal suspension (2 ml) was centrifuged at 
13,000 rpm at 4
o
C (Remi cooling centrifuge) for 30 min. 
Clear supernatant was decanted, and after suitable 
dilutions, the amount of unentrapped drug was estimated 
on UV spectrophotometer at 270 nm using phosphate 
buffer saline (pH7.4) as blank. Each study was carried 
out in triplicate (Mean±SD, n=3). The amount of drug 
entrapped in liposomes was calculated by following 
formula
34
. 
 
                            
                                               
                 
                        
2. Transmission electron microscopy study 
The size and the shape of 3TC loaded liposomes were 
confirmed by transmission electron microscopy (TEM) 
(Make Jeol Model JM 2100, accelerating Voltage 
200kV, resolution 0.24nm). In brief, the liposomes were 
suspended in nanopure water and ultrasonicated to 
disperse the particles.  A drop of the suspension was 
Godbole et al                                                                                                Journal of Drug Delivery & Therapeutics. 2018; 8(5-s):175-183           
ISSN: 2250-1177                                                                             [179]                                                                             CODEN (USA): JDDTAO 
placed on carbon-coated grids of 200 mesh, and allowed 
to dry. The size and shape was measured. 
3. Zeta potential 
The formulation stability is directly related to the 
magnitude of the surface charge. The liposomes were 
suspended in 10 ml distilled water and further diluted 
serially to obtain ratio of 1:1000 (v/v). Zeta potential 
was determined using Zetasizer (Malvern equipment).  
Each study was carried out in triplicate (Mean±SD, 
n=3). 
4. In-vitro release of 3TC 
The prepared 3TC loaded liposomal dispersion was 
centrifuged. The supernatant was discarded to eliminate 
untrapped 3TC. The deposited liposomes were 
reconstituted in 10 ml of phosphate buffer saline 
(pH7.4), and sonicated for 30 sec. An accurately 
measured volume of drug loaded liposomal suspension 
equivalent to 2 mg of drug was transferred in cellulose 
dialysis bag (a tube having 6.3 mm diameter with one 
end closed and molecular weight cut off between 12000-
14000, Himedia, Mumbai) which was pre soaked in 
distilled water for 24 h before dialysis to ensure 
complete wetting of membrane and removal of 
preservative. After closing the open end of the bag with 
a thread, it was vertically suspended in 250 ml beaker 
containing 200 ml phosphate buffer saline (pH7.4) at 
37±2
o
C, which was continuously being stirred at 300 
rpm with a magnetic stirrer. A care was taken to suspend 
the bag in such a manner that the whole bag remained 
immersed in the phosphate buffer saline
35
. The release 
of 3TC from liposome was compared with free drug by 
dissolving 2 mg 3TC in phosphate buffer saline (pH7.4) 
in similar bag.   
 For in-vitro release of 3TC, 5ml of phosphate buffer 
saline was withdrawn at predetermined intervals and 
subjected to estimate the amount of 3TC by 
spectrophotometer at 270 nm. The withdrawal of sample 
was replaced with same volume of fresh phosphate 
buffer saline (pH7.4). Each study was carried out in 
triplicate (Mean±SD, n=3) (Figure 3). 
5. Fourier Transfer Infra-Red spectroscopy 
Drug, cholesterol and phospholipid interaction study 
were carried out using FTIR Spectrophotometer 
(Shimadzu, Tokyo, Japan). The spectrum was recorded 
in the wavelength region of 4000-400 cm
-1
. 
The procedure involves dispersing individually the 
samples of 3TC, cholesterol and Phospholipon
®
 90H, 
and compressing into discs by applying a pressure of 5 t 
for 5 min in a hydraulic press. The pellets were placed 
in the light path and the spectrum was recorded. Initially 
a baseline correction was carried out using dry 
potassium bromide pellet. The FTIR spectrum of 
mixture of 3TC, cholesterol and Phospholipon
®
 90H 
were also taken by following same procedure.  
RESULTS AND DISCUSSION 
The objective of the present work was to find out the 
appropriate molar ratio of various 
phospholipid:cholesterol and the appropriate method for 
preparing liposome having vesicle size in the range 200-
300 nm with PDI below 0.500 and having maximum 
entrapment with delayed release of 3TC.  
The preliminary studies revealed that by employing 
different phospholipid:cholesterol molar ratio, thin film 
hydration method produced the vesicles in the size range 
of 231.5-431.0 nm and PDI from 0.212-1.00 and few 
phospholipid:cholesterol molar ratio produced 
liposomes of desired size and PDI (Table 1). Ether 
injection method produced the vesicles in the size range 
of 313.3-476.5 nm and PDI from 0.281-1.000 (Table 2). 
However, by ether injection method these phospholipids 
produced liposomes of very large size and none of the 
phospholipid: cholesterol molar ratio could produce 
vesicles in desired range, and PDI was above 0.500. 
Also, sonication of the dispersion could not lower the 
size to desired range and PDI remain higher than 0.500. 
Therefore, it was thought worthwhile to prepare 3TC 
loaded liposomes by thin film hydration method using 
the phospholipids and cholesterol in the molar ratios 
revealed by the primary study. However, the variables 
those can influence the size of vesicle in thin film 
hydration method were first optimized. This 
optimization study revealed that a relatively thinner film 
was obtained when the rotational speed of flask was 120 
rpm as compared to 80 rpm and 100 rpm. This may be 
due to higher speed might have favored even spreading 
and faster evaporation of chloroform. The thin film was 
hydrated with phosphate buffer saline (pH7.4) for 2, 4 
and 6 h. It was observed that 6 h of hydration resulted in 
to the vesicles of desired size and PDI. The final 
dispersion was subjected to sonication for 1 min. 
Sonication leads to rearrangement of lipid molecules 
and breakdown of multi-lamellar structure of vesicles. It 
was observed that 1 min sonication decreased the 
vesicle size and dispersion was less heterogeneous as 
compare to dispersion before sonication. Figure 1 is a 
prototype figure to represent the average vesicle size and 
PDI.
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Figure 1: Representative figure of vesicle size and PDI of the 3TC loaded liposomes  
 
1. Appearance 
Liposomes prepared by thin film hydration method were 
found to be milky in appearance. Phase separation was 
occurred in some formulations of liposomes prepared by 
ether injection method. Thin film hydration method 
generated superior liposomes compared with ether 
injection method. 
2. Vesicle size and PDI  
It was observed that as the concentration of lipid was 
increased, vesicle size was increased. Liposomes 
prepared by thin film hydration method produced the 
vesicles of size ranging from 231.5-431.0 nm and PDI 
from 0.212-1.000. Variation in vesicle size and PDI was 
observed, which may be due to the 
phospholipid:cholesterol molar ratio, preparation 
method and operating parameters which affects the size 
of the vesicles. 
3. Percentage encapsulation efficiency  
Encapsulation efficiency of liposomes was influenced 
by many factors such as, molar ratio of 
phospholipid:cholesterol, vesicle size and method of 
preparation
36
. To evaluate the effect of lipids on the 
encapsulation efficiency of drug, four different lipids 
viz. Phospholipon
®
 90H, Phospholipon
®
 90G, DPPC 
and DMPC were selected for study. The entrapment 
efficiency was found to be maximum with a formulation 
containing Phospholipon
®
 90 H and cholesterol in the 
molar ratio 1:2. Cholesterol has marked effect on 
encapsulation efficiency. It improves the fluidity and 
stability of bilayer membrane. Increasing the 
concentration of cholesterol imparts rigidity and 
increases the lipophilic properties of lipid bilayer, hence, 
increased in the entrapment of drug
37
. Encapsulation 
efficiency of the drug in liposomes was decreased in 
order of Phospholipon
®
 90H> Phospholipon
®
 90G > 
DPPC > DMPC from 39.0±2.60 - 63.80± 2.06 (Table 3 
and Figure 2). 
 
Figure 2: Percentage encapsulation efficiency of 
liposomal formulations 
4. Zeta potential determination 
The zeta potential measured for 3TC loaded liposomes 
was found to be -10.5±0.2 to        -13.7±0.3 mV, which 
indicated the liposomes having negative charge, which 
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is closer to range. Results demonstrated a low scope of 
coalescence of the vesicle systems and the potential for 
acceptable physical stability of formulated liposomes. 
5. In-vitro drug release study  
The drug release from liposomes depends on many 
factors including the composition of liposomes and the 
type of drug encapsulated. Once released, drug that 
normally crosses the membrane of a cell will enter the 
cell. At the end of 8 h study maximum 96.85±1.38% 
drug release was observed from liposomes. Thus, the 
release of 3TC from the liposomes could be contributed 
to the breaking of liposome structure. The leakage of 
liposome could be accounted by either liquefaction of 
liposomes or the force generated by stirring. Thus, 
liposomes containing 3TC gives steady release for 
longer period of time (Figure 3). 
It was observed that liposomal formulation TCLH3 
containing Phospholipon
®
 90H:cholesterol:drug in 1:2:1 
molar ratio produced milky white dispersion having 
vesicle size 273.0±2.04 nm and PDI 0.267±0.019. The 
entrapment efficiency was 63.64±3.29% which is 
highest amongst the studied lipids. Also, formulation 
TCLH3 released 96.85±1.38% drug, and showed 
extended release up to 8 h. The extended release may be 
contributed to concentration of cholesterol (Kirby et al., 
1980)
38
, and the transition temperature of lipid which 
retard the releases of drug. 
Hence, TCLH3 having  Phospholipon
®
 90H with better 
entrapment efficiency and extended in-vitro release was 
considered to be the best liposomal formulation for 
incorporation of 3TC. 
 
 
Figure 3: In-vitro release of 3TC at various time interval 
6. TEM study 
Liposome formation was confirmed by TEM photograph. The grid scan showed the spherical vesicles confirming the 
formation of liposomes (Figure 4). 
 
Figure 4: Representative TEM image of 3TC loaded liposome 
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7. FTIR study 
In FTIR spectrum of 3TC, cholesterol and Phospholipon
®
 90H physical mixture no significant difference in the 
characteristic peaks were observed. Indicating that there is no interaction between 3TC, cholesterol and Phospholipon
®
 
90H. (Figure 5).  
 
Figure 5: FTIR graph of 3TC, Phospholipid and their physical mixture 
 
CONCLUSIONS 
The conventional rotary vacuum evaporation method 
was found to be simple and suitable for the formation of 
3TC liposomal dispersion. Phospholipid:cholesterol 
molar ratio, method of preparation, hydration above 
transition temperature and hydration time were showed 
direct influence on vesicle size, PDI, percentage 
encapsulation and in-vitro release. The formation of 
liposomes was confirmed by TEM photography. Higher 
3TC encapsulation in liposomes will have long dosing 
intervals, and greater flexibility in dosing which 
ultimately will improve patient compliance and 
reduction in manufacturing cost. From the results it can 
be concluded that prepared liposomal formulation could 
serve as useful dosage form for the long term 3TC 
delivery to reduce the toxic effect during the therapy. 
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